Is Mobia Medical going out of business?

MOBIA MEDICAL, INC. (MOBI) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

MOBIA MEDICAL, INC. (MOBI) scores 34 out of 100 on fundamentals, Speculative / Volatile, based on SEC filing data.

Leading signal: Shares dilution YoY: 1108.12% (YoY)

Five questions, kept separate

Survival - Stable

21-30 mo of estimated runway from 2026-06-30, based on $177M of cash and short-term investments against $83.2M of annual burn. Adjusted shares outstanding increased 1108.1% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

51.6% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 1108.12% (YoY)
• Debt / Equity: -1.02x (Net Cash)
• ROIC: 49.32%
• Return on Assets: -30.69%
• FCF margin: -219.55% (Inv. Mode)
• Cash Runway (years): 2.13y
• R&D intensity: 17.78%
• Asset Growth Velocity: Rapid expansion presumed (high rev growth)
• Revenue per Asset Efficiency: -57.85% QoQ
• Cash Burn Deceleration: -75.99% QoQ improvement (Worsening)
• Working Capital Efficiency: 112.31x (Well-funded)
• Operating Leverage Inflection: OpEx/Rev declining (215.95%)

Read from filings through 2026-08-11.

Price as of 2026-09-09.